Literature DB >> 25218919

Supply of buprenorphine waivered physicians: the influence of state policies.

Bradley D Stein1, Adam J Gordon2, Andrew W Dick3, Rachel M Burns3, Rosalie Liccardo Pacula3, Carrie M Farmer3, Douglas L Leslie4, Mark Sorbero3.   

Abstract

Buprenorphine, an effective opioid use disorder treatment, can be prescribed only by buprenorphine-waivered physicians. We calculated the number of buprenorphine-waivered physicians/100,000 county residents using 2008-11 Buprenorphine Waiver Notification System data, and used multivariate regression models to predict number of buprenorphine-waivered physicians/100,000 residents in a county as a function of county characteristics, state policies and efforts to promote buprenorphine use. In 2011, 43% of US counties had no buprenorphine-waivered physicians and 7% had 20 or more waivered physicians. Medicaid funding, opioid overdose deaths, and specific state guidance for office-based buprenorphine use were associated with more buprenorphine-waivered physicians, while encouraging methadone programs to promote buprenorphine use had no impact. Our findings provide important empirical information to individuals seeking to identify effective approaches to increase the number of physicians able to prescribe buprenorphine.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Medicaid; Medication assisted treatment; Opioid use disorder; State policy

Mesh:

Substances:

Year:  2014        PMID: 25218919      PMCID: PMC4420477          DOI: 10.1016/j.jsat.2014.07.010

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  44 in total

1.  The contribution of insurance coverage and community resources to reducing racial/ethnic disparities in access to care.

Authors:  J Lee Hargraves; Jack Hadley
Journal:  Health Serv Res       Date:  2003-06       Impact factor: 3.402

2.  Do reimbursement delays discourage Medicaid participation by physicians?

Authors:  Peter J Cunningham; Ann S O'Malley
Journal:  Health Aff (Millwood)       Date:  2008-11-18       Impact factor: 6.301

Review 3.  Update in addiction medicine for the primary care clinician.

Authors:  Adam J Gordon; David A Fiellin; Peter D Friedmann; Marc N Gourevitch; Kevin L Kraemer; Julia H Arnsten; Richard Saitz
Journal:  J Gen Intern Med       Date:  2008-10-02       Impact factor: 5.128

4.  A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.

Authors:  R E Johnson; M A Chutuape; E C Strain; S L Walsh; M L Stitzer; G E Bigelow
Journal:  N Engl J Med       Date:  2000-11-02       Impact factor: 91.245

5.  From research to the real world: buprenorphine in the decade of the Clinical Trials Network.

Authors:  Walter Ling; Petra Jacobs; Maureen Hillhouse; Albert Hasson; Christie Thomas; Thomas Freese; Steven Sparenborg; Dennis McCarty; Roger Weiss; Andrew Saxon; Allan Cohen; Michele Straus; Gregory Brigham; David Liu; Paul McLaughlin; Betty Tai
Journal:  J Subst Abuse Treat       Date:  2010-06

Review 6.  Barriers to use of pharmacotherapy for addiction disorders and how to overcome them.

Authors:  Elizabeth M Oliva; Natalya C Maisel; Adam J Gordon; Alex H S Harris
Journal:  Curr Psychiatry Rep       Date:  2011-10       Impact factor: 5.285

Review 7.  Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

Authors:  M Connock; A Juarez-Garcia; S Jowett; E Frew; Z Liu; R J Taylor; A Fry-Smith; E Day; N Lintzeris; T Roberts; A Burls; R S Taylor
Journal:  Health Technol Assess       Date:  2007-03       Impact factor: 4.014

8.  Toxicity of buprenorphine overdoses in children.

Authors:  Bryan D Hayes; Wendy Klein-Schwartz; Suzanne Doyon
Journal:  Pediatrics       Date:  2008-04       Impact factor: 7.124

Review 9.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

10.  Buprenorphine versus methadone maintenance: a cost-effectiveness analysis.

Authors:  Christopher M Doran; Marian Shanahan; Richard P Mattick; Robert Ali; Jason White; James Bell
Journal:  Drug Alcohol Depend       Date:  2003-09-10       Impact factor: 4.492

View more
  46 in total

1.  High-Risk Prescribing to Medicaid Enrollees Receiving Opioid Analgesics: Individual- and County-Level Factors.

Authors:  Sara E Heins; Mark J Sorbero; Christopher M Jones; Andrew W Dick; Bradley D Stein
Journal:  Subst Use Misuse       Date:  2018-01-05       Impact factor: 2.164

2.  The payer's role in addressing the opioid epidemic: It's more than money.

Authors:  Todd Molfenter; Dennis McCarty; Nora Jacobson; Jee-Seon Kim; Sanford Starr; Mark Zehner
Journal:  J Subst Abuse Treat       Date:  2019-04-04

3.  Now is the Time to Address Substance Use Disorders in Primary Care.

Authors:  Richard Saitz; Timothy P Daaleman
Journal:  Ann Fam Med       Date:  2017-07       Impact factor: 5.166

Review 4.  Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.

Authors:  Michael S Toce; Peter R Chai; Michele M Burns; Edward W Boyer
Journal:  J Med Toxicol       Date:  2018-10-30

5.  County-level access to opioid use disorder medications in medicare Part D (2010-2015).

Authors:  Amanda J Abraham; Grace Bagwell Adams; Ashley C Bradford; William D Bradford
Journal:  Health Serv Res       Date:  2019-01-21       Impact factor: 3.402

6.  National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.

Authors:  Christopher M Jones; Melinda Campopiano; Grant Baldwin; Elinore McCance-Katz
Journal:  Am J Public Health       Date:  2015-06-11       Impact factor: 9.308

7.  States' implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence.

Authors:  Hannah K Knudsen; Michelle R Lofwall; Jennifer R Havens; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2015-10-09       Impact factor: 4.492

8.  Physicians as Mediators of Health Policy: Acceptance of Medicaid in the Context of Buprenorphine Treatment.

Authors:  Hannah K Knudsen; Jamie L Studts
Journal:  J Behav Health Serv Res       Date:  2019-01       Impact factor: 1.505

9.  Buprenorphine Prescribing Availability in a Sample of Ohio Specialty Treatment Organizations.

Authors:  Todd Molfenter; Carol Sherbeck; Mark Zehner; Sandy Starr
Journal:  J Addict Behav Ther Rehabil       Date:  2015

10.  Cost of pharmacotherapy for opioid use disorders following inpatient detoxification.

Authors:  Kathryn E McCollister; Jared A Leff; Xuan Yang; Joshua D Lee; Edward V Nunes; Patricia Novo; John Rotrosen; Bruce R Schackman; Sean M Murphy
Journal:  Am J Manag Care       Date:  2018-11       Impact factor: 2.229

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.